[go: up one dir, main page]

AR042087A1 - Tieno (3,2b) piridin - 6- carbonitrilos y tieno (2,3-b) piridin- 5- carbonitrilos como inhibidores de proteinquinasas - Google Patents

Tieno (3,2b) piridin - 6- carbonitrilos y tieno (2,3-b) piridin- 5- carbonitrilos como inhibidores de proteinquinasas

Info

Publication number
AR042087A1
AR042087A1 ARP030104277A ARP030104277A AR042087A1 AR 042087 A1 AR042087 A1 AR 042087A1 AR P030104277 A ARP030104277 A AR P030104277A AR P030104277 A ARP030104277 A AR P030104277A AR 042087 A1 AR042087 A1 AR 042087A1
Authority
AR
Argentina
Prior art keywords
nr4r4
aryl
alkenyl
nr4c
heteroaryl
Prior art date
Application number
ARP030104277A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR042087A1 publication Critical patent/AR042087A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona compuestos de fórmula (1a)-(1f).Los mismos son de utilidad en el tratamiento del cáncer, accidente cerebrovascular, osteoporosis, enfermedad renal poliquística, enfermedad autoinmune, artritis reumatoidea, y rechazo a transplante y los procesos para producir dichos compuestos. Reivindicación 1: Un compuesto de fórmula (1a) o fórmula (1b) o un S-óxido o S-dióxido del mismo en el cual X es -NH-, -NR4, -O-, -S(O)m, -NHCH2-; m es un número entero entre 0-2; n es un número entero entre 2-5; q es un número entero entre 0-5; R1 es un anillo fenilo opcionalmente sustituido con de 1 a 4 sustituyentes seleccionados entre el grupo que consiste de -J, -NO2, -CN, -N3, -CHO, -CF3, -OCF3, -R4, -OR4, -S(O)mR4, NR4R4, -NR4S(O)mR4, -OR6OR4, -OR6NR4R4, -N(R4)R6OR4, -N(R4)R6NR4R4, -NR4C(O)R4, -C(O)R4, -C(O)OR4, -C(O)NR4R4, -OC(O)R4, -OC(O)OR4, -OC(O)NR4R4, -NR4C(O)R4, NR4C(O)OR4, -NR4C(O)NR4R4, -R5OR4, -R5NR4R4, -R5S(O)mR4, -R5C(O)R4, -R5C(O)OR4, -R5C(O)NR4R4, -R5OC(O)R4, -R5OC(O)OR4, -R5OC(O)NR4R4, -R5NR4C(O)R4, -R5NR4C(O)OR4, -R5NR4C(O)NR4R4, o YR7; R2 es -H, -R3, -J, -C(O)XR3, -CHO, en el cual el grupo R3 puede estar sustituido por uno o más grupos seleccionados entre -C(O)XR8, -CHO, -C(O)Q, 1,3-dioxolano, -R8, -(C(R9)2)qXR8, -(C(R9)2)qQ, -X(C(R9)2)nXR8, -X(C(R9)2)nQ, o -X(C(R9)2)qR8; R3 es un alquilo C1-6, cis-alquenilo de C2-6, trans-alquenilo de C2-6, alquinilo de C2-6, arilo o heteroarilo; R4 es H, alquilo C1-6, cis-alquenilo C2-6, un trans-alquenilo C2-6, o un alquinilo C2-6; R5 es un grupo divalente que comprende alquilo C1-6, alquenilo C2-6, y alquinilo C2-6; R6 es un grupo alquilo divalente de C2-6; R7 es un anillo cicloalquilo de C3-7, un anillo arilo o heteroarilo, un arilo o heteroarilo fusionado con uno a tres anillos arilo o heteroarilo, en el cual cualquiera de los anillos arilo, cicloalquilo, o heteroarilo puede estar opcionalmente sustituido con de 12 a 4 sustituyentes seleccionados entre el grupo que consiste de -H, -arilo, -CH2-arilo, -NH-arilo, -O-arilo, -S(O)m-arilo, -J,-NO2, -CN, -N3, -CHO, -CF3, -OCF3, -R4, -OR4, -S(O)mR4, NR4R4, -NR4S(O)mR4, -OR6OR4, -OR6NR4R4, -N(R4)R6OR4, -N(R4)R6NR4R4, -NR4C(O)R4, -C(O)R4, -C(O)OR4, -C(O)NR4R4, -OC(O)R4, -OC(O)OR4, -OC(O)NR4R4, -NR4C(O)R4, NR4C(O)OR4, -NR4C(O)NR4R4, -R5OR4, -R5NR4R4, -R5S(O)mR4, -R5C(O)R4, -R5C(O)OR4, -R5C(O)NR4R4, -R5C(O)R4, -R5C(O)OR4, -R5C(O)NR4R4, R5OC(O)R4, -R5OC(O)OR4, -R5OC(O)NR4R4, -R5NR4C(O)R4, -R5NR4C(O)OR4, o -R5NR4C(O)NR4R4; R8 es -h, alquilo C1-6, cis-alquenilo de C2-6, trans-alquenilo de C2-6, alquinilo de C2-6, arilo o heteroarilo; R9 es -R4 o -F; Y es -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O), -NHSO2-, -SO2NH-, -C(OH)H-, -X(C(R9)2)q-, -(C(R9)2)q,-(C(R9)2)qX-, -C:::C-, cis y trans- -CH=CH- y cicloalquilo de C3-10; Q es NZZ´ en el cual Z y Z´ pueden ser iguales o diferentes y pueden ser H, alquilo C1-6, alquenilo de C2-6, alquinilo de C2-6, arilo o heteroarilo, y Z y Z´ junto con el N al cual están unidos pueden formar un anillo heterocíclico que puede tener un heteroátomo adicional seleccionado entre N, O, y S, opcionalmente sustituidos con -R4 sobre un C o un N, o sobre el N por un grupo -(C(R9)2)nR3, -C(R9)2)nZ"Z"´, o sobre el C por un grupo -(C(R9)2)qXR3, -(C(R9)2)qNZ"Z"´, Z" y Z"´ junto con el N al cual están unidos pueden formar un anillo heterocíclico que puede contener un heteroátomo adicional seleccionado entre N, O y S; Z"´ y Z" pueden seleccionarse entre H, alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, arilo o heteroarilo; y J es F, Cl, Br, y I, o una sal de los mismos aceptable desde el punto de vista farmacéutico.
ARP030104277A 2002-11-25 2003-11-19 Tieno (3,2b) piridin - 6- carbonitrilos y tieno (2,3-b) piridin- 5- carbonitrilos como inhibidores de proteinquinasas AR042087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42886202P 2002-11-25 2002-11-25

Publications (1)

Publication Number Publication Date
AR042087A1 true AR042087A1 (es) 2005-06-08

Family

ID=32393469

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104277A AR042087A1 (es) 2002-11-25 2003-11-19 Tieno (3,2b) piridin - 6- carbonitrilos y tieno (2,3-b) piridin- 5- carbonitrilos como inhibidores de proteinquinasas

Country Status (20)

Country Link
US (1) US6987116B2 (es)
EP (1) EP1565474A2 (es)
JP (1) JP2006509760A (es)
KR (1) KR20050086770A (es)
CN (1) CN1714092A (es)
AR (1) AR042087A1 (es)
AU (1) AU2003290802A1 (es)
BR (1) BR0316534A (es)
CA (1) CA2502614A1 (es)
CL (1) CL2003002287A1 (es)
EC (1) ECSP055802A (es)
MX (1) MXPA05004744A (es)
NI (1) NI200500089A (es)
NO (1) NO20051928L (es)
NZ (1) NZ540104A (es)
RU (1) RU2005120018A (es)
TW (1) TW200412950A (es)
UA (1) UA81000C2 (es)
WO (1) WO2004048386A2 (es)
ZA (1) ZA200504238B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2573538C (en) 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2006343808B2 (en) 2005-05-20 2012-03-29 Mirati Therapeutics, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
US20090099356A1 (en) * 2006-02-08 2009-04-16 Wyeth Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP2069359B1 (en) * 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
KR101428116B1 (ko) * 2006-08-21 2014-08-07 제넨테크, 인크. 아자-벤조푸라닐 화합물 및 사용 방법
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
RU2346947C1 (ru) * 2007-08-13 2009-02-20 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУВПО "КубГТУ") Способ получения фурилгетарилметанов, содержащих тиено[2,3-b]пиридиновый фрагмент
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
EP2240494B1 (en) * 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
KR20100137495A (ko) * 2008-03-05 2010-12-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
PE20110570A1 (es) * 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
PE20220139A1 (es) 2019-02-13 2022-01-27 Ptc Therapeutics Inc Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar
CN113195469B (zh) * 2019-02-19 2024-05-24 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2022169866A1 (en) * 2021-02-05 2022-08-11 Ptc Therapeutics Inc. Methods for treating spinocerebellar ataxia type 3
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45A (en) * 1836-10-11 Machine fob shelling cokm
EP0126970A3 (en) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytic and anti-depressant thienopyridine derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ID23978A (id) * 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
EP1950201A1 (en) * 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
DE60009888T2 (de) * 1999-04-21 2005-04-21 Wyeth Corp Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
WO2001047892A1 (en) * 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
WO2001094353A1 (en) * 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
AU2001295791A1 (en) * 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
EP1418917A1 (en) 2001-08-10 2004-05-19 Novartis AG Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia

Also Published As

Publication number Publication date
CA2502614A1 (en) 2004-06-10
ZA200504238B (en) 2009-09-30
US20040138251A1 (en) 2004-07-15
CN1714092A (zh) 2005-12-28
US6987116B2 (en) 2006-01-17
NZ540104A (en) 2007-05-31
MXPA05004744A (es) 2005-08-03
EP1565474A2 (en) 2005-08-24
UA81000C2 (en) 2007-11-26
ECSP055802A (es) 2005-08-11
NO20051928L (no) 2005-08-19
TW200412950A (en) 2004-08-01
NO20051928D0 (no) 2005-04-20
WO2004048386A3 (en) 2004-10-07
NI200500089A (es) 2006-01-11
AU2003290802A1 (en) 2004-06-18
BR0316534A (pt) 2005-10-04
CL2003002287A1 (es) 2005-01-14
JP2006509760A (ja) 2006-03-23
WO2004048386A2 (en) 2004-06-10
KR20050086770A (ko) 2005-08-30
WO2004048386A9 (en) 2005-07-14
RU2005120018A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
AR042087A1 (es) Tieno (3,2b) piridin - 6- carbonitrilos y tieno (2,3-b) piridin- 5- carbonitrilos como inhibidores de proteinquinasas
US7612217B2 (en) Sulfonium compound
CO5631435A2 (es) Proceso para la preparacion de 7-sustituido-3-quinolina y 3-quinol-4-ona carbonitrilos
ECSP003828A (es) Antagonistas de neurokinina selectivos
RU2014149149A (ru) БИЦИКЛИЧЕСКИЕ СУЛЬФОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORгамма АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
RU2014149136A (ru) ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
AR062715A1 (es) Procesos para la preparacion de acidos de 1,2,4- oxadiazol benzoico
AR050248A1 (es) Tieno (3,2-b) piridin-6-carbonitrilos como inhibidores de la quinasa proteica, procedimiento de preparacion del compuesto y composicion farmaceutuica que lo comprende
JP2013502451A5 (es)
JP2018536031A5 (es)
JP2014198688A (ja) 環状ポリスルフィド化合物の製造方法
JP5846044B2 (ja) （メタ）アクリル酸誘導体の製造方法
CN107001294A (zh) 一种用于制备钆布醇的方法
RU2014129937A (ru) Способы и промежуточные соединения для получения фармацевтических агентов
JP6819892B2 (ja) モノグリシジルイソシアヌレート化合物及びその製造方法
HU225458B1 (en) Process for the preparation of thiazole derivatives, intermediates and preparation thereof
AR117989A1 (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
US20200231613A1 (en) Phosphine oxides reduction
US12060374B2 (en) Silyl ether-containing sulfonate salt
JP2019534301A5 (es)
AR054849A1 (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
CZ289450B6 (cs) Způsob výroby nesymetricky substituovaných triazinů
JP2017149657A (ja) 有機ケイ素化合物およびそれを含む硬化性組成物
JPWO2002022566A1 (ja) 希土類三元錯体
US9365507B2 (en) Diaryl sulfone compound, and manufacturing method for same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal